Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target
Juan Carlos Montero, Alberto Ocaña, Mar Abad et al. · 2009
Read Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target by Juan Carlos Montero, Alberto Ocaña, Mar Abad et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0005565.txt.
Description
Juan Carlos Montero and co-authors studied a growth enzyme in early breast cancer in a 2009 PLOS ONE report. Breast cancer is the most common cancer in women, and some patients relapse even after treatment improves. Better markers are needed to tell which cancers will return.
The team measured an enzyme called Erk5 in early-stage tumours and tracked how patients fared. Tumours with more of the enzyme were linked to shorter disease-free times. That link makes Erk5 both a warning marker and a possible target for new drugs. A marker measured in the first tumour could help sort patients into closer or lighter follow-up.
Catalog record
| CREATOR | Juan Carlos Montero, Alberto Ocaña, Mar Abad et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005565